FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Large Molecule Drug Substance

Rasmus Pedersen, Ph.D., from FUJIFILM Diosynth Biotechnologies, outlines strategies to expand large-molecule production capacity to meet growing global medicine demand, noting the current gap that leaves 2 billion people without access.

FUJIFILM's global network spans the U.S., UK, Denmark, and Japan, with major investments to scale cell culture and microbial production. Key goals include boosting capacity, speeding tech transfers, increasing flexibility, and enhancing sustainability. Notable facilities include Denmark's 400,000-liter site and a new North Carolina facility modeled after it, both designed for scalable and flexible production from preclinical to commercial stages.

In this presentation, Pedersen likens the modular approach to Lego bricks, enabling adaptable and reliable growth. Learn more about the company's plans to provide clinical and commercial supply of life-changing medicines for patients around the globe by watching video below.